

health care consortia, health care providers, and researchers.  
 Partner surveys to be conducted by HRSA might include, for example, mail or telephone surveys of grantees to determine satisfaction with a technical assistance contractor, or in-class evaluation forms completed by providers who receive training from HRSA grantees to measure satisfaction

with the training experience. Results of these surveys will be used to plan and redirect resources and efforts as needed to improve service. Focus groups may also be used to gain partner input into the design of mail and telephone surveys. Focus groups in-class evaluation forms, mail surveys, and telephone surveys are expected to be the preferred methodologies.

A generic approval will permit HRSA to conduct a limited number of partner surveys without a full-scale OMB review of each survey. If generic approval is granted, information on each individual partner survey will not be published in the **Federal Register**.

The estimated response burden is as follows:

Type of survey	Number of respondents	Responses per respondent	Hours per response	Total hour burden
In-class evaluations .....	40,000	1	.05	2,000
Mail/Telephone surveys .....	12,000	1	.25	3,000
Focus groups .....	50	1	1.5	75
<b>Total .....</b>	<b>52,050</b>	<b>.....</b>	<b>.....</b>	<b>5,075</b>

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Wendy A. Taylor, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: February 16, 2000.

**Jane Harrison,**  
 Director, Division of Policy Review and Coordination.  
 [FR Doc. 00-4533 Filed 2-25-00; 8:45 am]  
**BILLING CODE 4160-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Resources and Services Administration**

**AGENCY:** Health Resources and Services Administration.

**ACTION:** Notice; correction.

**SUMMARY:** In the **Federal Register** issue of Thursday, August 18, 1999, make the following correction:

**Correction**

In the **Federal Register** issue of Wednesday, August 18, 1999, in FR Doc. 99-21257, on page 45027, the grant category beginning in the first column under the heading "Health and Welfare Technical Advisory Group (CFDA# 93.110AI)" is withdrawn from

competition due to consideration of alternative mechanisms to fund proposed activities.

Dated: February 18, 2000.

**James J. Corrigan,**  
 Associate Administrator for Management and Program Support.  
 [FR Doc. 00-4534 Filed 2-25-00; 8:45 am]  
**BILLING CODE 4160-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Submission for OMB Review; Comment Request; NIH Intramural Research Training Award, Program Application**

**SUMMARY:** Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the Office of the Director, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the **Federal Register** on Thursday, October 28, 1999, page 58071 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not

conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

**Proposed Collection**

*Title:* NIH Intramural Research Training Award, Program Application; *Type of Information Collection Request:* Revision of OMB No. 0925-0299; 4/30/2000; *Need and Use of Information Collection:* The proposed information collection activity is for the purpose of collecting data related to the availability of Training Fellowships under the NIH Intramural Research Training Award Program. This information must be submitted in order to receive due consideration for an award and will be used to determine the eligibility and quality of potential awardees. *Frequency of Response:* On occasion. *Affected Public:* Individuals seeking Intramural Training award opportunities. *Type of Respondents:* Postdoctoral, Predoctoral, Post-baccalaureate, Technical, and Student IRTA applicants.

*Estimated Number of Respondents:* 15,779. *Estimated Number of Responses Per Respondent:* 1. *Average Burden Hours Requested:* .53 *Estimated Total Annual Burden Hours Requested:* 8,422.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Type of respondent	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Postdoctoral IRTA .....	1,089	1	1	1,089
Predoctoral .....	6	1	1	6
Postbaccalaureate .....	290	1	1	290
Technical IRTA .....	27	1	1	27

Type of respondent	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Student IRTA .....	3,386	1	1	3,386
References for all IRTA categories .....	10,981	.....	.33	3,624
Total .....	15,779	1	.53	8,422

### Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and the clarity of information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

### Direct Comments to

Written comments and/or suggestions regarding the items contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Edie Bishop, Human Resource Consultant, Office of Human Resource Management, OD, NIH, Building 31, Room B3C07, 31 Center Drive MSC. 2203, Bethesda, MD, 20892-2203.

### Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: February 17, 2000.

**Frederick C. Walker,**

*Executive Officer, OD, NIH.*

[FR Doc. 00-4551 Filed 2-25-00; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Use of Thymosin $\beta$ 4 for Wound Healing Applications

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in any domestic or foreign applications corresponding to PCT Patent Application PCT/US99/17282 and USSN 60/094,960, both entitled "Thymosin  $\beta$ 4 Promotes Wound Repair" to Alpha1 Biomedicals, Inc., of Bethesda, Maryland. The patent rights in this invention have been assigned to the United States of America and Alpha1 Biomedicals, Inc. The prospective exclusive license may be limited to the development of therapeutic applications, including compositions and methods, to be used in the treatment of wounds and tissue repair.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before May 30, 2000 will be considered.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comment and other materials relating to the contemplated license should be directed to Susan S. Rucker, J.D., Patent and Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7056 ext 245; fax: 301/402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** The patent applications describe the use of the compound thymosin  $\beta$ 4, isoforms of

thymosin  $\beta$ 4 (T $\beta$ 4<sup>ala</sup>, T $\beta$ 9, T $\beta$ 11, T $\beta$ 12, T $\beta$ 13, T $\beta$ 14, or T $\beta$ 15) or a peptide derived therefrom, LKKTET, (aa residues 17-22) as an agent for promoting wound healing. Thymosin  $\beta$ 4 is a small, 43 mer, 4.9 kDa, peptide which can be produced by chemical synthesis or recombinantly. Studies using a punch model for wounds in rats have shown that providing thymosin  $\beta$ 4 either by systemic delivery (intraperitoneal) or topical delivery accelerates wound healing and that extracellular matrix deposition occurs in the wound bed. In addition, Thymosin  $\beta$ 4 has been shown previously to promote endothelial cell migration and to promote angiogenesis.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within ninety (90) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.*, a completed "Application for License to Public Health Service Inventions") in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 35 U.S.C. 552.

Dated: February 16, 2000.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 00-4553 Filed 2-25-00; 8:45 am]

**BILLING CODE 4140-01-P**